251 related articles for article (PubMed ID: 32819192)
1. Early serum infliximab trough level and mucosal healing could be predictors for one-year outcome after initiating therapy in Crohn's disease.
Tang J; Yang Q; Huang Z; Guo H; Chao K; Hu P; Gao X
Scand J Gastroenterol; 2020 Sep; 55(9):1035-1040. PubMed ID: 32819192
[TBL] [Abstract][Full Text] [Related]
2. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
3. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2009 Sep; 15(9):1295-301. PubMed ID: 19340881
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
[TBL] [Abstract][Full Text] [Related]
6. Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children.
El-Matary W; Walters TD; Huynh HQ; deBruyn J; Mack DR; Jacobson K; Sherlock ME; Church P; Wine E; Carroll MW; Benchimol EI; Lawrence S; Griffiths AM
Inflamm Bowel Dis; 2019 Jan; 25(1):150-155. PubMed ID: 29912413
[TBL] [Abstract][Full Text] [Related]
7. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
[TBL] [Abstract][Full Text] [Related]
8. [Association between drug trough concentration and disease outcome before infliximab maintenance treatment in children with Crohn's disease].
Deng X; Yu Y; Wang XQ; Li J; Xu X; Xu CD; Xiao Y
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Nov; 24(11):1246-1251. PubMed ID: 36398551
[TBL] [Abstract][Full Text] [Related]
9. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.
Davidov Y; Ungar B; Bar-Yoseph H; Carter D; Haj-Natour O; Yavzori M; Chowers Y; Eliakim R; Ben-Horin S; Kopylov U
J Crohns Colitis; 2017 May; 11(5):549-555. PubMed ID: 28453755
[TBL] [Abstract][Full Text] [Related]
10. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment.
Feng T; Chen B; Ungar B; Qiu Y; Zhang S; He J; Lin S; He Y; Zeng Z; Ben-Horin S; Chen M; Mao R
Inflamm Bowel Dis; 2019 Oct; 25(11):1813-1821. PubMed ID: 30934050
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic monitoring of infliximab therapy in Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila PE; Sipponen T; Färkkilä MA
Inflamm Bowel Dis; 2011 Apr; 17(4):947-53. PubMed ID: 20860048
[TBL] [Abstract][Full Text] [Related]
12. Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease.
Melek J; Štanclová M; Dědek P; Malý J; Bayer M; Pozler O; Bureš J
J Dig Dis; 2020 Dec; 21(12):705-710. PubMed ID: 32755026
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
14. [Neutrophil-lymphocyte ratio at 14th week predicts loss of response to 52-week infliximab therapy in patients with Crohn's disease].
Qian G; Hongxia D; Jin LI
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Apr; 40(4):453-458. PubMed ID: 32895126
[TBL] [Abstract][Full Text] [Related]
15. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
[TBL] [Abstract][Full Text] [Related]
16. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
17. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
18. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
19. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
